Last reviewed · How we verify
fezolinetant - reference formulation
At a glance
| Generic name | fezolinetant - reference formulation |
|---|---|
| Also known as | ESN364 |
| Sponsor | Shehzad Basaria, M.D. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (PHASE2)
- A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fezolinetant - reference formulation CI brief — competitive landscape report
- fezolinetant - reference formulation updates RSS · CI watch RSS
- Shehzad Basaria, M.D. portfolio CI